Profile
Ton focuses on the formation of novel companies in the immunology and immuno-oncology space.
He is a senior member at The Netherlands Cancer Institute and professor of Immunotechnology at Leiden University.
He was founder of AIMM Therapeutics and T cell factory (acquired by Kite Pharma), and has served as CSO of Kite Pharma EU.
For his work on T cell recognition in human cancer he received, amongst others, The Amsterdam Inventor Award, Queen Wilhelmina Cancer Research Award, Meyenburg Cancer Research Award, and William B.
Coley Award.
Ton carried out his Ph.D.
research with Hidde Ploegh, describing the rules of antigen presentation by MHC molecules, and carried out post-doctoral work with Peter Kim at The Whitehead Institute.
Ton Schumacher active positions
| Companies | Position | Start |
|---|---|---|
Neogene Therapeutics, Inc.
 Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | Founder | 2018-08-31 |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 2017-12-31 |
Kite Pharma EU BV
 Kite Pharma EU BV BiotechnologyHealth Technology Part of Gilead Sciences, Inc., Kite Pharma EU BV is a Dutch company dedicated to curing cancer. The company is based in Harlem, the Netherlands. The company specializes in cell therapy and immuno-oncology therapies that have the potential to transform the way cancer is treated. Kite Pharma was acquired by Kite Pharma, Inc., part of Gilead Sciences, Inc. from October 04, 2017 on March 17, 2015 for $275.56 million. | Chief Tech/Sci/R&D Officer | 2015-03-16 |
Former positions of Ton Schumacher
| Companies | Position | End |
|---|---|---|
AIMM Therapeutics BV
 AIMM Therapeutics BV Pharmaceuticals: MajorHealth Technology AIMM Therapeutics BV develops therapeutic antibodies for the treatment of cancer and infectious diseases. Its antibody discovery platform couples proprietary knowledge of B cell immortalization with the isolation of antibodies from humans or animals. The company was founded by Donald Kalff and Hergen Spits in 2004 and is headquartered in Amsterdam, the Netherlands. | Founder | - |
| NEON THERAPEUTICS, INC. | Founder | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
BioNTech US, Inc.
 BioNTech US, Inc. BiotechnologyHealth Technology BioNTech US, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA. | Health Technology |
Neogene Therapeutics, Inc.
Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | Health Technology |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Finance |
Kite Pharma EU BV
Kite Pharma EU BV BiotechnologyHealth Technology Part of Gilead Sciences, Inc., Kite Pharma EU BV is a Dutch company dedicated to curing cancer. The company is based in Harlem, the Netherlands. The company specializes in cell therapy and immuno-oncology therapies that have the potential to transform the way cancer is treated. Kite Pharma was acquired by Kite Pharma, Inc., part of Gilead Sciences, Inc. from October 04, 2017 on March 17, 2015 for $275.56 million. | Health Technology |
AIMM Therapeutics BV
AIMM Therapeutics BV Pharmaceuticals: MajorHealth Technology AIMM Therapeutics BV develops therapeutic antibodies for the treatment of cancer and infectious diseases. Its antibody discovery platform couples proprietary knowledge of B cell immortalization with the isolation of antibodies from humans or animals. The company was founded by Donald Kalff and Hergen Spits in 2004 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
- Stock Market
- Insiders
- Ton Schumacher
